TERAPEVTIChESKIE VOZMOZhNOSTI BENFOTIAMINA


Cite item

Full Text

Abstract

Diabetes mellitus (DM) remains one of the most serious chronic diseases that lead to disabling complications. Pilot clinical studies have actively studied thiaminpyrophosphate (thiamine and benfotiamine) for the prevention of complications of diabetes. The results of 4 randomized, blind clinical studies have confirmed the efficacy of benfotiamine in the treatment of diabetic polyneuropathy. A number of experimental studies have shown prospects of benfotiamine for the treatment of diabetic nephropathy, retinopathy, and cardiomyopathy in DM. Thus, the benfotiamine has multiphasic effects in the treatment of DM, and opens new possibilities for pathogenetic treatment of vascular complications.

About the authors

Irina Vladimirovna Gur'eva

References

  1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
  2. Booth AA, Khalifah RG, Hudson BG. Thiamin pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun. 1996;220:113-19.
  3. Gleiter CH, Schreeb KH, Freudenthaler S. Comparative bioavailability of two vitamin Bl preparations: Benfotiamin and thiamin mononitrate. In Gries FA, Federlin K. Benfotiamin in the Therapy of Polyneuropathy. New York: Georg Thieme Verlag, 7998/29-33.
  4. Grefo A, Bi'fsch R. Comparative bioavailability of various thiamin derivatives after oral administration. Int J Clin Pharmacol Ther 1998(4):276-27.
  5. Ledermann H. Wiedney K.D. Therapiewoche 1989;39:1445-49.
  6. Stracke H, Gauss W, Achenbach U, et al. Benfotiamin in Diabetic Polyneuropathy (BENDIP): Results of a randomized, Double-blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008;116:600-05.
  7. Valkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diab Obes Metab. 2008;10:99-108.
  8. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diab 1996; 104:311-36.
  9. Haupt E, Ledermann H, Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy - a three week randomized, controlled, pilot study (Bedip-study). International J. Clin Pharmacol Ther 2005;43(2):71-7.
  10. Balakumar P, Arora MK, Reddy J, et al. Pathogenesis of diabetic nephropathy: involvement of multifaceted signalling mechanism. J. Cardiovasc Pharmacol 2009;54:129-38.
  11. Balakumar P, Chakkarwar VA, Krishan P, et al. Vascular endothelial dysfunction: a rug of war in diabetic nephropathy? Biomed Pharmacother 2009;63:171-79.
  12. Bakker SJ, Heine RJ, Gans RO. Thiamine may indirectly act as an antioxidant. Diabetologia 1997;40:741-42.
  13. Thornalley PJ, Babaei-Jadidi R, Al Ali H, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007;50:2164-70.
  14. Balakumar P, Chakkarwar VA, Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem 2009;320:149-62.
  15. Alkhalaf A, Klooster A, Oeveren WV, et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010;33:1598-601.
  16. Hammes HP, Du X, Edelstein D, Taguchi T, et al. Benfotiamine block three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-99.
  17. Tarallo S, Beltramo E, Berrone E, et al. Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells. Acta Diabetol 2009; doi: 10.1007/s00592-009-0124-5.
  18. Wu S, Ren J. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosei Lett 2006;394:158-62.
  19. Balakumar P, Kaur T, Singh M. Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions. Toxicology 2008;245:49-64.
  20. Stirban A, et al. Abstract 41th EASD Meeting, Athens Greece, 10-15 Sept. 2005
  21. Stirban A, Negrean M, StratmannB, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006;29:2064-71.
  22. Yadav UCS, Kalariya NM, Srivastava SK, et al. Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages. Free Radical Biol Med 2010;(12)4С:5.
  23. Katare RG, Caporali A, Oikawa A, et al. Vitamin B1 Analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1 - mediated survival pathway. Circ Heart Fail 2010;3(2):294-305.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies